Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
Geron (Nasdaq: GERN) announced participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Company management will join a fireside chat on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, Florida.
A live and archived audio webcast will be available via the Investors & Media section of Geron’s website.
Positive
- None.
Negative
- None.
News Market Reaction – GERN
In the Jun 1 session, GERN declined 3.20%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Employee equity grants | Neutral | -0.8% | Inducement stock options for five new employees under Nasdaq Rule 5635(c)(4). |
| May 12 | Clinical data update | Positive | +0.7% | Positive real-world RYTELO data in LR-MDS and planned EHA/ASCO presentations. |
| May 06 | Q1 2026 earnings | Positive | -4.2% | Strong RYTELO revenue, narrowed loss, reiterated 2026 guidance and progress updates. |
| May 05 | Investor conferences | Neutral | +5.1% | Planned presentations at Bank of America and Stifel oncology investor events. |
| Apr 22 | Earnings date notice | Neutral | +3.3% | Announcement of Q1 2026 results date and related conference call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent event-driven moves have generally been modest, with one notable negative reaction to earnings despite seemingly constructive fundamentals.
Over the last few months, Geron has mixed operational and investor-relations catalysts. A May 2026 real-world RYTELO® study and planned data at EHA/ASCO saw a small positive move, while Q1 2026 results with $51.8M RYTELO revenue and a narrowed net loss of $3.6M drew a -4.24% reaction. Investor conference announcements in May produced a 5.1% gain, suggesting that visibility events can matter. Today’s Goldman Sachs conference participation fits that pattern of ongoing outreach and communication with investors.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m. ET in Miami, FL.
A live and archived audio webcast of the fireside chat will be available through the Investors & Media section of Geron’s website at www.geron.com.
About Geron
Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
